Drug intelligence / Profile preview

CAN04 + gemcitabine + nab-paclitaxel

Development stage: Unknown
Lead developer: Cantargia
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

CAN04 + gemcitabine + nab-paclitaxel is a three-drug combination regimen for the treatment of advanced or metastatic pancreatic cancer. CAN04 (nadunolimab) is a fully humanized monoclonal IgG1 antibody targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), blocking IL-1α and IL-1β signaling and triggering antibody-dependent cellular cytotoxicity (ADCC). Gemcitabine is a nucleoside analog antineoplastic agent inhibiting DNA synthesis, and nab-paclitaxel (albumin-bound paclitaxel) is a microtubule inhibitor delivered via nanoparticle-formulated albumin for improved tumor uptake. This regimen is being investigated for increasing efficacy and clinical benefit beyond the standard gemcitabine + nab-paclitaxel combination.

Other names: Nadunolimab + gemcitabine + nab-paclitaxel

Targets

IL1RAP (Interleukin 1 receptor accessory protein)

Beyond the preview

Go deeper on CAN04 + gemcitabine + nab-paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAN04 + gemcitabine + nab-paclitaxel.

Explore the full profile